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Abstract 
Pediatric Acute Lung Injury (ALI) is associated with a high mortality and morbidity, and 
dysregulation of matrix metalloproteinases (MMPs) may play an important role in the 
pathogenesis and evolution of ALI. Here we examined MMP expression and activity in pedi-
atric ALI compared with controls. MMP-8, -9, and to a lesser extent, MMP-2, -3, -11 and -12 
were identified at higher levels in lung secretions of pediatric ALI patients compared with 
controls. Tissue Inhibitor of Matrix metalloproteinase-1 (TIMP-1), a natural inhibitor of 
MMPs was detected in most ALI samples, but MMP-9:TIMP-1 ratios were high relative to 
controls. In subjects who remained intubated for ≥10 days, MMP-9 activity decreased, with > 
80% found in the latent form. In contrast, almost all MMP-8 detected at later disease course 
was constitutively active. Discriminating MMP-9:TIMP-1 ratios were found in those who had 
a prolonged ALI course. These results identify a specific repertoire of MMP isoforms in the 
lung secretions of pediatric ALI patients, and demonstrate inverse changes in MMPs -8 and -9 
with protracted disease.   
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INTRODUCTION 
Matrix metalloproteinases (MMPs) are involved 
in many normal homeostatic mechanisms. However, 
accumulating data suggests that MMP dysregulation 
can contribute to the pathology of chronic lung dis-
orders, such as asthma (1-2), emphysema (3), chronic 
obstructive pulmonary disease (4), bronchopulmon-
ary dysplasia (5-6) and cystic fibrosis (CF) (7-8). High 
levels of MMP-2, -8, and -9 have also been demon-
strated in lung diseases with an acute onset, such as 
adult ALI and Acute Respiratory Distress Syndrome 
(ARDS) (9-12) and Respiratory Distress Syndrome 
(RDS) of the newborn (5). MMP isoform expression 
and activity in pediatric ALI, however, remains 
largely unknown. Unique aspects of MMP expression 
and activity might be predicted in this population 
relative to others, since the causes of pediatric ALI 
differ from those of acute respiratory failure in other 
age groups, with a strikingly higher incidence of viral 
lower respiratory tract disease leading to ALI in chil-
dren compared to adults (13-14).  
Here we report MMP expression and activity 
profiles in pediatric ALI subjects compared with well 
pediatric controls, including examination of TIMP 
expression. We hypothesized that a unique MMP 
profile exists in lung secretions of pediatric ALI sub-
jects, and that dysregulated MMP activity may play a 
role in the pathogenesis and evolution of this disease. 
We identified increased MMP-8 and -9 activities in 
pediatric ALI with corresponding expression of 
TIMP-1. In those with persistent disease, MMP-9 ac-
tivity dropped later in the disease course relative to 
MMP-8 activity, which remained elevated. Our find-
ings highlight important changes in MMP isoform 
expression and activity with disease state, and may Int. J. Med. Sci. 2009, 6 
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identify novel disease biomarkers and potential tar-
gets for intervention. 
MATERIALS AND METHODS 
ALI subjects 
Lung secretions were collected via endotracheal 
suctioning from intubated pediatric patients with a 
known diagnosis of ALI within 24 hours of intuba-
tion, with serial samples collected approximately 
every 12 hours for the duration of intubation. Samples 
were collected with a suction cannula (8F-12F, de-
pending on endotracheal tube size) inserted past the 
end of the endotracheal tube. All subjects were en-
rolled consecutively over a 1 year period. Approval 
from the Institutional Review Board at The University 
of Alabama at Birmingham and informed consent was 
obtained prior to sample collection. Exclusion criteria 
for the study included immunosuppresion (recent 
steroids or cytotoxic therapy), transplantation or fail-
ure to obtain study consent.  
Definition of Acute Lung Injury 
ALI was defined as hypoxemia (ALI PaO2/FiO2 
≤ 300 mm Hg, ARDS PaO2/FiO1 ≤ 200), bilateral in-
filtrates on frontal chest radiograph, pulmonary ar-
tery occlusion pressure ≤ 18 mm Hg when measured, 
or no clinical evidence of left atrial hypertension (15). 
Virus-induced ALI was defined as ALI caused by any 
viral etiology as determined by a positive rapid viral 
screen (direct fluorescent antibody for RSV, adenovi-
rus, influenza A or B or parainfluenza virus) or viral 
culture. 
Control subjects 
Control subjects were pediatric patients with no 
known lung disease undergoing elective surgical 
procedures in the Operating Room (OR). All subjects 
screened for chronic lung disease prior to surgery 
were excluded from the study. Samples were obtained 
during the standard care of the endotracheal tube, 
which was typically performed in the earlier portions 
of the procedures. No patient identifiers were col-
lected with these samples. Predominant diagnoses 
within the controls included elective tonsillectomies 
and/or adenoidectomies, with a median age of 4 
years. 14 subjects were enrolled over a 3 month pe-
riod. 
Endotracheal aspirate processing 
Once collected, endotracheal tube aspirates were 
centrifuged at 1000 RPM at 4°C for 10 minutes. The 
supernatant was collected, protein concentration was 
measured as described by the manufacturer (Bio-Rad, 
Catalog # 5000112), and separate aliquots were saved 
at 4° C for immunoblotting and quantitative analysis 
as outlined below. 
Detection of MMP and TIMP isoforms by 
Western Blot analysis 
All patient samples were electrophoresed on 
SDS-polyacrylamide gels (20 µg protein/ sample was 
loaded for each immunoblot lane) according to a 
modified method by Laemmli (16) and electroblotted 
onto Immobilon-P PVDF membranes. Membranes 
were blocked in Tris buffer (pH=7.4) containing 5% 
powdered milk for one hour, washed and incubated 
with primary antibody of interest overnight at 4°C. 
After incubation, samples were washed with borate 
saline (100 mM boric acid, 25 mM Na borate, 75 mM 
NaCl) and incubated with species-specific IgG horse-
radish peroxidase conjugates (at dilutions of 1:5000) 
for one hour. Immunoblots were then developed us-
ing ECL chemiluminescent kits (GE Healthcare, Pis-
cataway, NJ). 
Zymography 
To measure total gelatinase activity, zymogra-
phy was performed on all patient samples using a 
modification of a technique previously described (17). 
In brief, samples (10 ug protein/sample) were sub-
jected to electrophoresis through 7.5% polyacrylamide 
gels containing 1 mg/ml porcine skin gelatin in the 
presence of SDS under non-reducing conditions. Fol-
lowing electrophoresis, gels were washed in 2.5% 
Triton X-100 for 1 hour at 4°C, then incubated in 50 
mM TRIS, 5 mM CaCl2 for 16 hours at 37°C. Gels were 
stained for 30 minutes in Coomassie blue and de-
stained for 1-2 hours.  
Measurement of MMP-8, MMP-9, and TIMP-1 
activity 
MMP-8, -9 and TIMP-1 activity were quantified 
using ELISA-based activity assays (F8M00, F9M00, 
DTM100; R and D systems, Minneapolis, MN). The 
manufacturer’s sensitivity (minimum detectable con-
centration) for individual kits was 0.021 ng/ml for 
MMP-8, 0.005 ng/ml for MMP-9 and 0.08 ng/ml for 
TIMP-1. Briefly, samples and recombinant enzyme 
standards were incubated for two hours at room 
temperature in 96-well plates coated with monoclonal 
antibodies for MMP(s) (MAB 908 for MMP-8 and 
MAB 911 for MMP-9) of interest, followed by activa-
tion with 1 mM aminophenylmercuric acetate 
(APMA), a chemical activator of MMPs. After incuba-
tion for another two hours at 37°C, a fluorogenic sub-
strate (Fluor-Pro-Leu-Gly-Leu-Ala-Arg-NH2) was 
placed in each well and the plate was incubated at 
37°C for 18 hours. The plate was then read on a spec-
trophotometer (SpectraMax Gemini, Molecular De-Int. J. Med. Sci. 2009, 6 
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vices, Sunnyvale, CA; excitation and emission wave-
length of 320 and 405, respectively) and data was 
quantified using standard curves provided with the 
kits. For the studies of TIMP-1, samples and recom-
binant TIMP-1 standards were incubated for two 
hours at room temperature in 96-well plates coated 
with TIMP-1 monoclonal antibodies. Bound TIMP-1 
was then conjugated with a horseradish peroxi-
dase-based secondary antibody for one hour. A col-
orimetric substrate (hydrogen peroxide and chroma-
gen) was placed in each well and color change was 
quantified on a colorimeter (Bio-Rad, Hercules, CA) 
within 30 minutes via standard curves provided with 
the kits. 
Reagents 
The following primary monoclonal antibodies 
were used to immunoblot for the various MMPs and 
TIMPs of interest. MMP-8 (MAB 3316; Chemicon), 
MMP-9 (MAB 911; R/D Systems), MMP-2 (MAB 9022; 
R/D Systems), MMP-3 (MAB 905; R/D Systems), 
MMP-11 (MAB 3365; Chemicon), MMP-12 (MAB 919; 
R/D Systems), MMP-1 (MAB 901; R/D Systems), 
MMP-7 (MAB 9071; R/D Systems), MMP-10 (MAB 
910; R/D Systems), MMP-19 (RP3MMP19; Triple 
Point Biologics, Inc, Forest Grove, OR), MMP-26 
(RP2MMP26; Triple Point Biologics, Inc), MMP-27 
(RP2MMP27; Triple Point Biologics, Inc), TIMP-1 
(MAB 970; R/D Systems) and TIMP-2 (MAB 971; R/D 
Systems). All recombinant MMPs and TIMPs were 
purchased through either R and D Systems (Minnea-
polis, MN) or Chemicon (Temacula, CA).  
Statistics 
Descriptive statistics including mean and stan-
dard error of the mean (SEM) were determined for all 
continuous data. ANOVA, paired and unpaired t-tests 
were used for comparisons of MMP and TIMP activi-
ties utilizing Sigmastat statistical software (Jandel, 
CA). A p-value < 0.05 was used to determine statisti-
cal significance. As this was an exploratory study to 
examine MMP expression and activity in the study 
group relative to controls, no formal power calcula-
tions were performed in advance of sample collection. 
RESULTS 
Expression of MMP and TIMP Isoforms in Pe-
diatric ALI 
  Table 1 provides a summary of demographic 
and diagnostic information regarding the pediatric 
ALI subjects. The diagnoses and ages of ALI subjects 
were typical for those normally cared for in this terti-
ary PICU. 68% of patients enrolled met criteria for 
ARDS, the most severe form of ALI. Global mortality 
was 16% while 44% of subjects had multi organ fail-
ure. 
Table 1: Demographic and diagnostic information of study 
subjects 
   ALI (all)  †Prolonged 
ALI 
Number 25  12 
ARDS 17  9 
Admission 
PaO2/FiO2  
(Mean ± SEM) 
159 ± 13 
 
143 ± 17 
 
Admission OI index 
(Mean ± SEM) 
24 ± 3  29 ± 5 
Age:  
Median (Range) 
6 yr  
(1mo - 18yr) 
4.6 yr  
(1mo - 13yr) 
Gender 
M/F 
15/10 7/5 
Pneumonia (8)  Pneumonia (4) 
Sepsis (6)  Sepsis (3) 
Asthma (4)  Aspiration (2) 
Bronchiolitis (2)  Asthma (2)  
Aspiration (2)  Trauma (1) 
Acute chest syndrome (1)   
Pulmonary hemorrhage (1)  
Diagnosis 
Trauma (1)   
Steroids 4  2 
Multi Organ Failure  11  6 
Death 4  2 
†Prolonged ALI: ALI and ventilator days ≥ 10. 
 
 
  Figure 1 provides a plot of the number of ALI 
subjects and their duration of intubation. Based on the 
inherently bimodal distribution of the data (for the 
purposes of our analysis), and the lack of consensus 
regarding definitions of early or late ALI (11, 18), 
subjects who were extubated before day 10 (N=13) 
were defined as ‘short course’ ALI, while those who 
were not were defined as ‘prolonged ALI’ (meeting 
ALI criteria and requiring intubation ≥10 days, N=12 
subjects). The average number of intubated days for 
this group of patient was 17 versus 4 days in those 
with a ‘short course’ ALI (p < 0.0009). Thus, this 
natural breakpoint defined two patient groups with 
vastly different needs for ventilatory support. To de-
fine the MMP profile of all ALI subjects, lung secre-
tions collected from days 0 to 10 of intubation for each 
subject were pooled and probed for MMP isoform 
expression by zymography and western blotting. 
Samples were pooled due to occasional inadequate 
sample volumes that limited longitudinal analysis. An 
example of gelatinase activity found in lung samples 
from one subject over time is shown in Figure 2A, 
demonstrating a rapid increase and progression over 
days 0-4 of disease. MMP-8 and MMP-9 were identi-
fied in the majority of ALI samples (Figures 2B and 
2C), with lower levels of MMP-2, -3, -11 and -12 de-Int. J. Med. Sci. 2009, 6 
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tected in some ALI samples (data not shown). Other 
MMPs screened but not detected included MMPs 
-1,-7,-10,-19,-26 and -27. Lung secretions were also 
probed for expression of natural MMP inhibitors 
TIMP-1, and -2. Only TIMP-1 was detected in the 
majority of ALI samples, while antibodies to TIMP-2 
failed to identify this inhibitor in screened samples. 
 
 
Figure 1: Number of ventilator days for each ALI subject 
(N=25). 12 ALI patients went on to have a protracted 
course, requiring ventilatory support for ≥ 10 days. The 
mean number of intubated days for this subgroup was 
17±3.3 days, compared to 4±0.6 days for the rest of the ALI 
subjects (Mean±SEM; p< 0.0009). 
MMP-8 and MMP-9 Activity in Pediatric ALI 
  Based on the results of our screening summa-
rized in Figure 2, we examined the activities of 
MMP-8 and MMP-9 in all ALI subjects (N=25, days 
0-10) compared to controls. Active MMP-8 was 
up-regulated in ALI subjects, with an approximately 
7-fold increase compared to controls (Figure 3A, p < 
0.004). Total MMP-8 activity, determined post APMA 
stimulation of latent MMP-8 was elevated approxi-
mately 3.5-fold (Figure 3B, p < 0.04). Figure 4 sum-
marizes mean active and total (including detection of 
latent MMP-9 by APMA stimulation) MMP-9 activity 
in ALI samples, demonstrating that both active and 
total MMP-9 activity was up-regulated (approxi-
mately 3-fold higher when compared with control 
values, p < 0.0003). Because viral respiratory infec-
tions are a common cause of bronchiolitis and pneu-
monia that lead to ALI in the pediatric population, we 
examined MMP-8 and MMP-9 activities in vi-
rus-induced ALI compared with non-viral ALI. We 
found insignificant elevations in total MMP-8 and 9 
activities in subjects with viral ALI (RSV=4, Parain-
fluenza=2) compared to non-viral ALI subjects (viral 
ALI MMP-8=49±22 ng/mg, non-viral ALI MMP-8=24 
±9 ng/mg; p≈ 0.3; viral ALI MMP-9=582 ± 300 ng/mg, 
non-viral ALI MMP-9=402±57 ng/mg; p≈ 0.4). 
 
 
Figure 2: Expression of MMP-8 and MMP-9 in pediatric 
ALI. For 2B-2C, each lane represents lower airway secre-
tions from a separate ALI subject. ‘+’ represents recom-
binant MMP of interest as positive control. 2A. Zymogram 
(7.5% SDS non-reduced gel) demonstrates increasing ge-
latinase activity in lung samples from one ALI subject over 
time. Each lane represents a sample obtained every 12 hrs 
from time of intubation to Day 4. 2B. Western blot (7.5% 
SDS reduced gel) demonstrates prominent MMP-8 staining 
(70 kDa, black arrow) in ALI samples. The faint higher 
molecular weight bands at ~85kDa (grey arrow) likely 
represent pro-MMP-8 isoforms. 2C. Western blot (7.5% 
SDS non-reduced gel) shows prominent MMP-9 staining (78 
kDa, black arrow) in ALI samples. The higher molecular 
weight band at 135 kDa (grey arrow) is consistent with 
lipocalin:MMP-9 complexes.  
 
TIMP-1 and MMP-9:TIMP-1 Activity in Pediat-
ric ALI 
Since TIMP-1 normally provides negative regu-
lation to MMP-9 in tissue compartments, we exam-
ined TIMP-1 activity and MMP-9:TIMP-1 activity ra-
tios in our ALI samples (all subjects, N=25, days 0-10) 
compared with controls. Although TIMP-1 was de-
tectable in the lung secretions of most ALI subjects, 
there was no significant difference in activity between 
ALI and control subjects (ALI=137±19 ng/mg, con-
trol=109±13 ng/mg; p≈ 0.4), leading to a higher MMP- 
9:TIMP-1 activity ratios in the ALI samples compared 
to controls (Figure 5, p < 0.006). We then examined Int. J. Med. Sci. 2009, 6 
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these parameters in subjects who went on to have a 
prolonged course of ALI (ventilatory support for ≥10 
days, N=12). MMP-9 and MMP-9:TIMP-1 activity ra-
tios in ‘short course’ ALI (N=13 subjects, samples 
from days 0-10) were higher than those in compli-
mentary samples from the ‘prolonged ALI’ subjects 
(N=12 subjects, samples from days 0-10) (Table 2). 
Thus, high MMP-9:TIMP-1 activity ratios during days 
0-10 correlated with subjects who exhibited more 
rapid disease resolution within our study population. 
Table 2: MMP-9 activity, TIMP-1 activity, and 
MMP-9:TIMP-1 activity ratios (days 0-10) of short course 
ALI compared with prolonged ALI 
  Short course ALI   
(N=13)   
Prolonged ALI 
(N=12) 
MMP-9 activity   
(±SEM) 
599±129 ng/mg  372±112 ng/mg 
TIMP-1 activity   
(±SEM) 
127±34 ng/mg  155±21 ng/mg 
MMP-9:TIMP-1 
activity ratio 
(±SEM) 
12±4* 2.7±0.9 
*p< 0.03 
 
 
 
Figure 3: Mean (±SEM) MMP-8 activity in ALI subjects 
(N=25) relative to controls (N=14). Total MMP-8 level was 
measured following chemical stimulation of samples with 
APMA (1 mM) to activate latent MMP-8. 3A. Active MMP-8 
is up-regulated in lung secretions of ALI subjects compared 
to controls (ALI=33±8.9 ng/mg, control=4.7±1 ng/mg; * p < 
0.004). 3B. Total MMP-8 activity is higher in lung secretions 
of ALI subjects compared to controls (ALI=61±20 ng/mg, 
control=17±3 ng/mg; * p < 0.04). 
 
 
 
Figure 4: Mean (±SEM) MMP-9 activity in ALI subjects 
relative to controls. Total MMP-9 level was measured fol-
lowing chemical stimulation of samples with APMA (1 mM) 
to activate latent MMP-9. 4A. Active MMP-9 is up-regulated 
in ALI lung secretions compared to controls (ALI= 490±85 
ng/mg, control=147± 39 ng/mg; * p < 0.0005). 4B. Total 
MMP-9 is up-regulated in ALI lung secretions compared to 
controls (ALI= 668±88 ng/mg, control=230± 63 ng/mg; * p 
< 0.0003). 
 
 
 
 
 
Figure 5: Mean MMP-9:TIMP-1 activity ratio in ALI subjects 
was approximately 8-fold higher when compared to con-
trols (* p < 0.006). 
 Int. J. Med. Sci. 2009, 6 
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Change in MMP-8 and MMP-9 Activity with 
ALI progression 
  We next analyzed MMP-8 and MMP-9 activity 
in the subgroup of subjects with a prolonged course of 
ALI (N=12). For these studies, MMP activities in 
pooled samples from days 0-10 and ≥ 10 days were 
compared for each subject. Active MMP 8 and -9 (ie: 
endogenous levels at baseline, prior to chemical 
stimulation with APMA) and total MMP levels 
(post-APMA stimulation, which activates latent 
MMPs present in samples) are shown (Figures 6A and 
6B). Total MMP-8 remained high with ALI persis-
tence, with almost 97% detected in the active form. In 
contrast, MMP-9 levels dropped after day 10 of intu-
bation, with most activity seen post-APMA stimula-
tion, reflecting the predominant presence of 
pro-MMP-9 isoforms. 
 
 
Figure 6: Active and total MMP-8 and MMP-9 levels in ALI 
with disease progression. 6A. Mean (± SEM) MMP-8 activity 
is shown for subjects who developed prolonged ALI (all 
subjects requiring ventilatory support ≥ 10 days, N=13). 
With ALI progression, using pooled samples from days ≥ 10, 
active MMP-8 level increased by approximately 2-fold. > 
97% of total MMP-8 found was active in later samples 
compared to 47% in pooled samples < 10 days. 6B. Active 
and total MMP-9 levels decreased by approximately 21 and 
6-fold respectively with ALI progression [* p < 0.004 for 
active and † p < 0.0002 for total MMP-9 activity in earlier 
ALI (days 0-10) compared with later ALI (≥ 10 days)]. In 
later stages of ALI, > 80% of total MMP-9 detected were 
present as pro-enzymes. 
 
Due to the persistently active MMP-8 phenotype 
seen in the prolonged ALI group, we examined 
MMP-8 expression characteristics for each ALI subject 
over the disease time course (Figures 7A and 7B). 
Most of the detectable MMP-8 isoforms in the day 
0-10 pooled samples was approximately 72 kDa. In 
contrast, lower molecular weight MMP-8 isoforms (50 
and 60 kDa) were detected in the pooled samples 
from subjects after day 10 of disease. Together, the 
results indicate that with ALI disease progression, 
MMP-9 activity decreases while MMP-8 activity re-
mains abnormally elevated, with the emergence of 
lower molecular weight MMP-8 isoforms. 
 
 
 
 
 
Figure 7: MMP-8 expression shifts to a lower molecular 
weight isoform in protracted disease. Each lane represents 
pooled lower airway secretions from a separate ALI sub-
ject. ( ‘+’ represents recombinant MMP-8 positive control.) 
7A. Western blot (7.5% SDS reduced gel) demonstrates 
prominent MMP-8 staining at approximately 70 kDa (black 
arrow) in pooled ALI samples from study subjects (< 10 
days). Faint MMP-8 staining is seen at a lower molecular 
weight (60 kDa, white arrow). 7B. Western blot (7.5% SDS 
reduced gel) shows prominant MMP-8 staining at 60 kDa 
(black arrow) and 50 kDa (white arrow) in lower airway 
secretions from later ALI samples (pooled from days ≥ 10). 
Faint staining is seen at higher molecular weight (84 kDa, 
grey arrow).  
 Int. J. Med. Sci. 2009, 6 
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DISCUSSION 
  Acute lung injury is a clinical and pathological 
entity characterized by diffuse alveolar-capillary wall 
damage causing severe impairment in oxygenation 
(19). MMPs are known to play an important role in 
inflammation and in extracellular matrix remodeling. 
This study aimed to assess the pulmonary expression 
of MMPs and their inhibitors in the clinical course of 
pediatric ALI, including comparison to healthy con-
trols. 
  Due to a large number of potential MMP sub-
strates and cells of origin in the lung, our initial 
screening included a comprehensive number of MMP 
isoforms. From this screen, only MMP-2, -3 -8, -9, -11 
and -12 were detected via immunoblotting. Specifi-
cally, a robust expression of neutrophil-derived 
MMPs (MMP-8 and -9) was appreciated in the vast 
majority of ALI samples. We also found that only 
TIMP-1 was consistently detected in our ALI samples, 
with significantly higher MMP-9:TIMP-1 ratios ob-
served relative to controls. Notable differences were 
seen in MMP-9:TIMP-1 activity ratios of subjects with 
a prolonged ALI course (ALI ≥ 10 days). Pooled sam-
ples from the first 10 days of intubation demonstrated 
that those with a ‘short course’ had a 4-fold higher 
MMP-9:TIMP-1 activity ratio relative to those who 
went on to have a protracted course (Table 2). Lan-
chou et al. reported a similar trend with higher 
MMP-9:TIMP-1 ratios in their ARDS group that rap-
idly resolved (< 4 days) compared with their more 
prolonged ARDS group (> 8 days) (11). Another study 
demonstrated an increase in MMP-9 and NGAL levels 
(neutrophil gelatinase-B associated lipocalin complex) 
in lung fluid obtained on postnatal days 2 and 4 from 
premature infants recovering from RDS, when com-
pared to infants with RDS who went on to develop 
chronic lung disease (20). These observations suggest 
that higher levels of total MMP-9 activity and 
MMP-9:TIMP-1 activity ratios in ALI may potentially 
serve a protective role and prevent further disease 
progression.  
  Notable differences were seen in MMP-9 and 
MMP-8 expression profiles and regulation with ALI 
progression. MMP-9 activity decreased with disease 
progression and existed predominantly as 
pro-enzymes. In contrast, MMP-8 activity remained 
elevated with ALI persistence, with the emergence of 
lower molecular weight MMP-8 isoforms (Figure 7B) 
rather than the neutrophil-derived isoforms seen 
during the early stages of disease (Figure 2B). Lower 
molecular weight MMP-8 isoforms are expressed and 
released by resident mesenchymal cells of the lung 
(21-22), and secreted promptly into the extracellular 
space following synthesis (in contrast to the storage 
and release of MMP-8 from neutrophil granules, 
where luminal detection predominates (23)). We 
speculate that in earlier stages of ALI, MMP-9 and -8 
are primarily released by activated neutrophils that 
have entered the pulmonary compartment. With dis-
ease progression and reduction in the acute, neutro-
phil dominated inflammatory response, MMP-9 levels 
decrease. In contrast to MMP-9, MMP-8 expression 
remained elevated in subjects with a prolonged 
course (Figure 6A), and we speculate that this may be 
due in part to additional release of lower molecular 
weight active MMP-8 isoforms from resident lung 
cells (Figure 7B). The failure to detect significant 
TIMP-2 expression in ALI samples could contribute to 
the absence of MMP-8 regulation seen in our samples. 
In an adult study, Prikk et al. identified mesenchymal 
derived MMP-8 in addition to neutrophil derived 
MMP-8 in patients with bronchiectasis, which is 
characterized by chronic inflammation and remodel-
ing of the bronchial architecture (21). Future studies 
designed to clarify the source of MMP-8 expression in 
early and late ALI disease will aid in our under-
standing of MMP contributions to ALI progression 
and resolution in the pediatric population.  
  ALI secondary to viral infection is much more 
common in children compared with adults (24). In our 
studies, we found a trend towards higher MMP-8 and 
-9 levels in subjects with ALI caused by paramyxovi-
rus-induced respiratory failure compared with 
non-viral ALI that was not significant. Several inves-
tigators have reported a relationship between viral 
respiratory infection and MMP-9 induction (25-27). 
Our studies were likely limited by the relatively small 
number of patients with confirmed viral infection 
(n=6), but still extend previous reports to pediatric 
ALI patients, suggesting a positive relationship be-
tween viral-induced ALI and MMP-9 activity in hu-
man subjects.  
  There are limitations to the current study that 
s h o u l d  b e  n o t e d .  O u r  a n alysis was performed on 
pooled ALI samples which may prevent direct com-
parison with other studies that have used samples 
from different time points in the course of ALI. Be-
cause our data demonstrated a natural breakpoint in 
ALI persistence at days 8-10 (Figure 1), ‘short course’ 
and ‘prolonged course’ ALI were defined for subse-
quent analysis by this breakpoint. Different studies 
have used different definitions for early and late ALI, 
with no clear consensus among investigators (11, 18). 
Although our choice of 10 days to define ‘short ‘ and 
‘long’ course ALI is seemingly arbitrary, it was natu-
rally defined by our data, and segregated our patients 
into two groups with large differences in ventilatory Int. J. Med. Sci. 2009, 6 
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requirements. Additionally, due to the small quanti-
ties of lung secretions obtained during our studies, 
extensive analysis for other markers of neutrophil 
activity and other features of lung inflammation were 
not performed. Finally, bronchoalveolar lavage fluid 
was not collected in our study, and therefore direct 
analysis of the alveolar compartment relative to tra-
cheal-derived secretions was not performed. Despite 
these limitations, our findings of a limited repertoire 
of MMP expression, TIMP-1 identification, elevated 
MMP-9:TIMP-1 activity ratios, and changes in MMP-8 
isoform expression over time are in agreement with 
those reported by several authors, and help to provide 
a measure of validity to our observations. 
 
CONCLUSION 
In summary, we identified a unique repertoire of 
MMP expression in lung secretions of pediatric ALI 
patients, with MMP-8 and -9 significantly 
up-regulated in comparison to controls. In patients 
with a prolonged ALI course, MMP-9 activity de-
creased with disease progression, while MMP-8 ac-
tivity remained abnormally elevated. A shift to lower 
molecular weight MMP-8 isoforms was detected with 
ALI progression, potentially identifying a role of 
mesenchymal derived MMP-8 in prolonged ALI. Our 
findings lend support to further investigations to 
clarify the roles of MMPs -8 and -9 on disease mani-
festations. 
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